CRISPR-edited allogeneic CAR-T company whose vispa-cel (CB-010) matched autologous CAR-T efficacy in lymphoma in 2025 data.
Vispacabtagene regedleucel (CD19, chRDNA-edited) holds RMAT, Orphan, and Fast Track designations for B-NHL; ANTLER phase 1 data (November 2025) showed efficacy and durability on par with autologous products and outpatient-compatible safety; enrolling ~20 more second-line LBCL patients to confirm an HLA-matching strategy; IND cleared in lupus.
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares CRISPR functional genomics, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares Allogeneic donor and iPSC master cell banks, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/